Respiratory News and Research

RSS

Males at higher risk of severe COVID-19 and mortality in Indian case study

A new US-based study by researchers at Dartmouth College, the Development Data Lab, IDFC Institute, Johns Hopkins University, and the University of Chicago shows that the infection fatality rate (IFR) could be twice as high for men compared to women and increases much less at older ages compared to high-income countries.

7 Jan 2021

Which strain should SARS-CoV-2 vaccine candidates target?

A researcher at Clemson University, USA, has recently explored how governments might effectively combat the pandemic through strategic vaccination as new variants and strains of the virus emerge. The study suggests that vaccine candidates should target the fast-spreading variant, even when the initial prevalence is much lower.

7 Jan 2021

In Los Angeles and beyond, oxygen is the latest covid bottleneck

As Los Angeles hospitals give record numbers of covid patients oxygen, the systems and equipment needed to deliver the life-sustaining gas are faltering.

7 Jan 2021

Severe COVID-19 recovered patients do not display long-lasting adaptive immune responses, finds study

A team of scientists from the University of Valencia and INCLIVA Health Research Institute, Spain, has recently investigated the durability of immune responses specifically developed against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative pathogen of coronavirus disease 2019 (COVID-19).

7 Jan 2021

New approach produces strong antidotal efficacy in treating lethal botulism in animals

Related to new research published in the January issue of Science Translational Medicine, Patrick McNutt, PhD, of the Wake Forest Institute for Regenerative Medicine, was part of the research team that demonstrated a new "Trojan horse" approach that produces strong antidotal efficacy in treating lethal botulism in mice, guinea pigs and rhesus macaque monkeys.

7 Jan 2021

Danish study suggests local lockdown had no effect on SARS-CoV-2 infection rate

The onset of the coronavirus disease 2019 (COVID-19) pandemic led to severe restrictions on public mobility and interaction, national or state-wide lockdowns, school and workplace closures, and curfews. The result was widespread economic hardship, in addition to the toll on health.

7 Jan 2021

ACE2 receptor is responsible for the wide host range of SARS-CoV-2

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is thought to have a zoonotic origin, perhaps originating in a bat coronavirus with an unknown intermediate host. It is not only very infectious but has been found to infect a wide range of mammals, including dogs, cats, ferrets, hamsters, and minks, besides non-human primates. This range may be still higher, claims a recent preprint that appeared in January 2021 on the bioRxiv server.

6 Jan 2021

Researchers analyze evaporation and propagation of respiratory droplets of COVID-19 patients

COVID-19 can be transmitted when an infected person talks, coughs, sneezes or sings, expelling virus-containing respiratory droplets that can reach the mouth, nose or eyes of previously uninfected people.

6 Jan 2021

Is one-dose COVID-19 vaccination better than two?

A recent study published on the preprint server medRxiv in December 2020 reflects on the possibility of using a single-dose vaccine regimen to accomplish large-scale vaccination as early as possible.

6 Jan 2021

More stringent measures may be needed to control new SARS-CoV-2 B.1.1.7 variant in England

Researchers in the UK have conducted a comprehensive epidemiologic analysis of the new severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) variant in an effort to learn more about the expanded range and frequency of coronavirus disease 2019 (COVID-19) cases in England.

6 Jan 2021

In-silico modeling provides new understanding of immune response to SARS-CoV-2

The COVID-19 pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has crippled global healthcare systems and triggered an economic crisis in many countries. The pandemic is not showing signs of a slowdown even in 2021 with a new and more infectious variant of the virus wreaking havoc in the UK and many other parts of the world.

6 Jan 2021

Study shows durable specific humoral immunity against SARS-CoV-2 after mild or asymptomatic infection

As a part of the COMMUNITY (COVID-19 Immunity) study, researchers from Sweden reveal long-lasting IgG neutralizing antibody response against spike glycoprotein of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the vast majority of convalescent individuals – even after asymptomatic or mild infection. Their results are currently available on medRxiv* preprint server.

6 Jan 2021

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

RedHill Biopharma Ltd., a specialty biopharmaceutical company, today announced that RHB-204 has been granted Fast Track designation by the U.S. Food and Drug Administration for its development as a potential first-line, stand-alone, oral treatment of pulmonary nontuberculous mycobacteria (NTM) disease caused by Mycobacterium avium Complex (MAC) - a rare disease for which there is no FDA-approved first-line therapy.

6 Jan 2021

Neutralization antibodies affected by only a few mutations to the SARS-CoV-2 receptor-binding domain

In a recent bioRxiv* preprint paper, US researchers mapped in detail how mutations to the receptor-binding domain (RBD) of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) affected antibody binding in convalescent human serum – and revealed that it is influenced by mutations at only a handful of dominant epitopes.

6 Jan 2021

Study: Dual use of cigarettes and e-cigarettes may not cut risk of cardiovascular disease

Cardiovascular disease is the leading cause of death associated with smoking cigarettes. But as use of e-cigarettes ("vaping") becomes more popular, including as a way to cut back on cigarettes, little is known about its effect on cardiovascular health.

6 Jan 2021

Respiratory News and Research

Males at higher risk of severe COVID-19 and mortality in Indian case study

Which strain should SARS-CoV-2 vaccine candidates target?

In Los Angeles and beyond, oxygen is the latest covid bottleneck

Severe COVID-19 recovered patients do not display long-lasting adaptive immune responses, finds study

New approach produces strong antidotal efficacy in treating lethal botulism in animals

Danish study suggests local lockdown had no effect on SARS-CoV-2 infection rate

ACE2 receptor is responsible for the wide host range of SARS-CoV-2

Researchers analyze evaporation and propagation of respiratory droplets of COVID-19 patients

Is one-dose COVID-19 vaccination better than two?

More stringent measures may be needed to control new SARS-CoV-2 B.1.1.7 variant in England

In-silico modeling provides new understanding of immune response to SARS-CoV-2

Study shows durable specific humoral immunity against SARS-CoV-2 after mild or asymptomatic infection

RedHill Biopharma: RHB-204 receives FDA Fast Track designation for treatment of NTM disease

Neutralization antibodies affected by only a few mutations to the SARS-CoV-2 receptor-binding domain

Study: Dual use of cigarettes and e-cigarettes may not cut risk of cardiovascular disease

NIAID set to conduct large monoclonal SARS-CoV-2 antibody clinical trial

Vitamin D supplementation found to reduce COVID-19-related mortality, says study

Evidence review: COVID-19 infections are generally 'mild' in children under five years

Disulfide-reducing agents demonstrate potential antiviral activity against SARS-CoV-2

Modified Vaccinia Ankara model vaccine prevents COVID-19 in transgenic mice study

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News